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Crystals and nano- and microparticles form inside the human body from
intrinsic proteins, minerals, or metabolites or enter the body as particulate
matter from occupational and environmental sources. Associated tissue
injuries and diseases mostly develop from cellular responses to such crystal
deposits and include inflammation, cell necrosis, granuloma formation, tis-
sue fibrosis, and stone-related obstruction of excretory organs. But how do
crystals and nano- and microparticles trigger these biological processes?
Which pathomechanisms are identical across different particle types, sizes,
and shapes? In addition, which mechanisms are specific to the atomic or
molecular structure of crystals or to specific sizes or shapes? Do specific
cellular or molecular mechanisms qualify as target for therapeutic interven-
tions? Here, we provide a guide to approach this diverse and multidisci-
plinary research domain. We give an overview about the clinical spectrum
of crystallopathies, about shared and specific pathomechanisms as a con-
ceptual overview before digging deeper into the specialty field of interest.
Introduction
Atoms or ions aggregating in a periodic manner
endorse a spontaneous self-perpetuating growth of reg-
ular-shaped crystals. Organisms also catalyze the
aggregation of atoms and ions into amorphous crystals
and use these to create endo- or exoskeletal structures
such as corals, shells, bones, or teeth [1]. In the wrong
place, the same process can be injurious, for example,
extraskeletal calcifications of vascular walls or tendons.
Single crystals glued together can grow up to polycrys-
talline masses such as calculi or stones. Indeed, numer-
ous diseases are caused by or at least associated with
deposition of crystals, misfolded proteins, or airborne
particulate matter at nano-, micro-, or macroparticle
size [1] (Table 1). Similar to infectious organism, it is
often not the agent itself causing health problems but
rather the body’s own responses originating from
life-saving ancient danger response programs [2,3].
Such responses include necroinflammation [4],
immunothrombosis [5], granuloma formation, and tis-
sue fibrosis [6]. Other diseases relate to stone forma-
tion and ductal obstructions [7–9]. The discovery of
the NACHT, LRR, and PYD domains-containing pro-
tein 3 (NLRP3) inflammasome as a universal signaling
platform that converts the uptake of very diverse
microparticles into secretion of interleukin (IL)-1b/IL-
18 and the subsequent inflammation has raised broad
attention across different research domains [10,11].
This landmark insight posed a number of important
research questions such as: Do other shared pathome-
chanisms across different crystallopathies exist or are
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there also unique pathomechanisms specific to single
molecular crystal entities, crystal shapes, or sizes [2]?
Here, we provide a guide into general concepts of this
research domain, highlight some of the recent research
activities, and provide key references for further
reading.
Crystal formation and handling in
human diseases
Supersaturation of solutes often results in the forma-
tion of microcrystals, which serves as a nidus for crys-
tal growth in vitro. Inside the human body, the
excretory organs are especially prone to crystallization
upon supersaturation since they concentrate ions from
body fluids to facilitate excretion, for example, via the
urinary and biliary tract. Certain pathological condi-
tions involve formation of crystals inside the human
body such as vascular calcification and atherosclerosis.
Furthermore, misfolded proteins are known to form
self-aggregates leading to the formation of fibrillary
proteins, for example, a-synuclein in Parkinson’s dis-
ease or tau and amyloid-beta in Alzheimer’s disease.
Interestingly, a recent study reported that under cer-
tain conditions, protein fibrils form protein crystals—
the most stable form of proteins consuming less energy
than fibrils on the energy landscape of protein folding
[12]. Indeed, the deposition of amyloid crystals, and
not amyloid fibrils, might be the main pathomecha-
nisms of progressive neurodegenerative diseases and
warrants further exploration. Moreover, certain drugs
also tend to crystallize in the human body, for exam-
ple, acyclovir, indinavir, amoxicillin, and methotrexate
(MTX) [13,14]. In addition, dying cells form crystals
of uric acid, as well as eosinophil granule releases form
Charcot–Leyden crystals (CLCs) that serve as danger-
associated molecular patterns (DAMPs) and trigger
inflammation [15,16]. Another route of exposure to
crystals and crystalline particles is environmental expo-
sures where particulates enter the human body from
the outside. For example, airborne occupational, envi-
ronmental particulate matter enters the lungs via
inhalation and eyes via direct exposure. Cosmetics,
metallic, plastic or silicone implants, dental materials
[17,18], as well as nanoparticles used as drug carriers,
represent extrinsic sources of crystalline particles.
Of note, the human body has evolved mechanisms
to minimize exposures to crystalline particles. For
example, eyelashes and nasal hair protect eyes and
lungs from airborne occupational and environmental
particulate matter exposures. Tears and mucus facili-
tate rapid clearance of particulate matter from external
and internal surfaces. On the corneal surface of the
eyes, the first-line defender cells of the innate immune
system—the neutrophils—trap airborne particulates by
forming neutrophil extracellular traps (NETs), and
aggregated clots containing crystals and NETs are
cleared as eye rheum [19]. Acids and enzymes in the
intestinal tract degrade ingested particles. Conversely,
the physiological response of our body to intrinsic
crystals is quite different and involves multiple mecha-
nisms determined by particle size. Neutrophils, macro-
phages, and other phagocytes usually phagocytose
particles within the nano- to micrometer size range
[20]. Lytic proteases try to degrade engulfed particles
in phagolysosomes, failure of which can result in lyso-
some destabilization, leakage of lysosomal content into
the cytosol, cell stress, autophagy or necrosis, and
inflammation. When the particle cargo is significant,
macrophages appear as foam cell. Alternatively,
macrophages fuse together to form giant cells enabling
engulfment of larger particles [21,22]. Inability to han-
dle larger particles leads to frustrated phagocytosis,
resulting in necrosis and inflammation [20]. Crystal
exposures ending in frustrated phagocytosis by neu-
trophils license the release of NETs [23,24]. Further-
more, polycrystalline particles that aggregate and grow
to the size of calculi and stone can fill body cavities
and ducts up to mechanical obstruction and organ
failure, for example, in diseases such as biliary colic,
unilateral or bilateral renal colic, nephrocalcinosis,
acute pancreatitis, and sialolithiasis [13,25,26]. Several
mechanisms promote crystal growth in vivo—for exam-
ple, crystal adhesion molecules such as CD-44, annexin
II, osteopontin, pentraxin-3, or uromodulin/Tamm–
Horsfall protein-1 in the urinary tract [27,28]. Tumor
necrosis factor receptor signaling induces the expres-
sion of these molecules on the tubular lumen as a
starting point for nephrocalcinosis [29]. In addition,
NETs contribute to the formation and growth of gall-
stones [30].
The crystal masses also cause vascular obstructions
—for example, cholesterol crystal (CC) dislocating
from ruptured atherosclerotic plaques of larger vessels
can enter the bloodstream [31]. Such CC showers end
in smaller peripheral arteries of the skin, intestinal
tract, or kidneys and cause obstruction, tissue infarc-
tion, and organ failure, that is, CC embolism [21,32].
In addition, vascular calcifications in the medial layer
of arteries cause calciphylaxis [33]. Together, crystals
may form inside the human body via various physio-
logical processes as well as enter the human body from
various extrinsic sources like air pollution, and occu-
pational, environmental dust and induce colic, inflam-
mation, and tissue necrosis, and occasionally might
lead to organ failure.
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Table 1. Guide to crystal- and microparticle-related diseases. COPD, chronic obstructive pulmonary disease.
Crystalline material Pathomechanisms Disorder and disease manifestation References
Amorphous and mineral-based solids
Air pollutants, volcano
ashes
Necroinflammation, tissue
fibrosis
Smog-related asthma, pneumonitis, COPD [87,88]
Calcium carbonate Inflammation, NETs, and
aggNETs formation
Gall ducts/bladder: Cholecysto-/docholithiasis [1]
Nanoparticles (e.g., formed
by titanium dioxide,
carbon, polystyrene,
metallic, nanodiamonds)
Necroinflammation,
inflammation
Kidney/Ureter: Nephro-/urolithiasis
Tissue injury, mesothelioma, asthma,
cardiovascular disease, malignancy
[89–91]
Tobacco smoke
particulates
NLRP3 inflammasome ? Smoking-related COPD, emphysema [92,93]
Protein- and purine-derived crystals
Adenine Tissue fibrosis Adenine phosphoribosyltransferase deficiency,
nephro-/urolithiasis
[80]
b-Amyloid (protein
aggregates and amyloid
fibrils)
NLRP3 inflammasome
activation
Dementia, hyperglycemia, polyneuropathy,
cardiomyopathy
[12,94]
Bile pigment Necroinflammation Bile cast nephropathy, pancreatitis,
cholecystolithiasis or docholithiasis
[95]
Charcot–Leyden crystals NLRP3 inflammasome
activation
Eosinophilia, infection with helminths,
hematologic malignancies
[16,96]
Hemozoin NLRP3 inflammasome
activation
Malaria [81,82]
Light chains NLRP3 inflammasome
activation
Light-chain Fanconi syndrome, myeloma cast
nephropathy, crystalloglobulinemia, fibrillary
glomerulonephritis, cast nephropathy
[26,97,98]
Myoglobin or heme NLRP3 inflammasome
activation
Myoglobin cast nephropathy [99,100]
Uromodulin glycoprotein Inflammasome activation [71]
Fibrous material
Asbestos Lung fibrosis, NLRP3
inflammasome activation,
fibrosis
Asbestosis, asbestos-mediated mesothelioma [101,102]
Cotton, silk Inflammation, fibrosis Cotton dust lung disease [103]
Crystalline solids
Small or short microparticles (1–10 µm in size)
Calcium oxalate
monohydrate and
dehydrate
Necroinflammation, tissue
fibrosis
Nephro-/urolithiasis, acute oxalate
nephropathy, chronic oxalate nephropathy
(primary hyperoxaluria)
[29,63]
Calcium pyrophosphate
or calcium phosphate
Necroinflammation Pseudogout, chondrocalcinosis,
hemochromatosis, hyperparathyroidism,
hyperphosphatemic familial tumoral
calcinosis, vascular calcification, calciphylaxis,
warfarin calcification, Dent‘s disease,
nephrocalcinosis
[17,104,105]
Cystine Inflammation, NLRP3
inflammasome activation,
fibrosis
Cystinosis [106,107]
Silica Chronic inflammation,
granuloma, lung fibrosis
Silicosis [108,109]
Large/long microparticles (10–100 µm in size)
Cholesterol Necroinflammation,
immunothrombosis
Atherosclerosis, cholesterol embolism,
nonalcoholic steatohepatitis, cholesteryl
ester storage disease,
cholecysto-/docholithiasis
[31,51] (C. Shi, T. Kim, S.
Steiger, S. R. Mulay, B. M.
Klinkhammer, T. B€auerle,
M. E. Melica, P.
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How do crystals activate cells from
the outside and enter into intracellular
compartments?
Exogenous crystals such as silica and titanium can
interact with a number of different surface receptors
on macrophages and other cells (Fig. 1) [34]. For
example, the transmembrane scavenger receptors (SR)
SR-A1, SR-B1, CD36, and macrophage receptor with
collagenous structure (MARCO) [35,36] can contribute
to lung injury and fibrosis in animals exposed to occu-
pational dust particulate such as silica or asbestos
fibers [37,38]. CD36 is another member of this family
that facilitates the phagocytic uptake of crystalline par-
ticles and fibers [39]. Outside-in signaling or phagocy-
tosis via such SRs can engage with the NLRP3
inflammasome in resident and infiltrating macrophages
[35,39,40]. The physiological role of these receptors
rather relates to host defense, phagocytic clearance of
dead cells, or cellular uptake of lipid particles includ-
ing high-density lipoprotein particles that have a key
role on cholesterol transport [41–43].
Other surface receptors are involved in the outside-in
signaling of endogenous crystals and microparticles [34].
C-type lectin (Clec)-12a is a surface receptor expressed
by dendritic cells and macrophages that has been
described to respond to uric acid microcrystals released
by dying cells [15]. Interestingly, Clec-12a signaling inhi-
bits the pro-inflammatory signaling pathways related to
the tyrosine kinase Syk, while eliciting pro-inflamma-
tory effects by augmenting type I interferon signaling
[15,44]. CD16/FcɣRIII and complement factors potenti-
ate the response to monosodium urate crystals (MSU)
[45,46]. As another mechanism, uric acid crystals can
Table 1. (Continued).
Crystalline material Pathomechanisms Disorder and disease manifestation References
Romagnani, L. Yang, D.
M€ockel, M. Baues, E.
Mammadova-Bach, B.
Sanne, J. W. M.
Heemskerk, A. Braun, T.
Lammers, P. Boor, H. J.
Anders, unpublished
observation)
Drugs: Acyclovir,
indinavir, amoxicillin,
MTX
Necroinflammation, tissue
fibrosis
Drug-related kidney injury [13,14,110,111]
Monosodium urate Necroinflammation Acute or tophaceous gout, acute urate
nephropathy
[11,75,112]
Polycrystalline solids
Large microcrystals (100 µm–1 cm in size)
Calculi or stones of
multiple crystalline materials
and proteins
Tissue fibrosis, granuloma
formation
Biliary colic, nephrocalcinosis, sialoliths, acute
pancreatitis, unilateral or bilateral renal colic,
gallstones
[8,30]
Cholesterol Immunothrombosis Thrombosis and foreign body reaction [5] (C. Shi, T. Kim, S.
Steiger, S. R. Mulay, B. M.
Klinkhammer, T. B€auerle,
M. E. Melica, P.
Romagnani, L. Yang, D.
M€ockel, M. Baues, E.
Mammadova-Bach, B.
Sanne, J. W. M.
Heemskerk, A. Braun, T.
Lammers, P. Boor, H. J.
Anders, unpublished
observation)
Monosodium urate Aggregated NETs, tissue
fibrosis, granuloma
formation
Tophi, chronic urate nephropathy,
nephrolithiasis
[76,113,114]
Implants (plastic or
silicone)
Tissue fibrosis, granuloma
formation
Aseptic osteolysis, foreign body reactions [115,116]
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also directly interact with lipid structures of the outer
plasma membrane of dendritic cells and induce Syk
kinase signaling potentially by spatial rearrangements of
signaling elements in cholesterol-rich lipid rafts [47].
Cholesterol crystals seem to activate cells also via
activation of the alternative complement pathway and
tumor necrosis factor [48–50]. CC-mediated cell death is
unrelated to mixed lineage kinase domain-like (MLKL)
kinase-dependent (necroptosis), gasdermin D (inflamma-
some-dependent pyroptosis), caspase 8 (apoptosis), Ca2+
influx, K+ efflux, and SYK but involves direct plasma
membrane destabilization as CC plates extract choles-
terol from the plasma membrane [51]. These effects
relate to the lipid nature of CCs and are different from
those of most other crystals and nano- and microparti-
cles that enter cells via phagocytosis.
How do crystals activate cells from
the inside to induce
necroinflammation?
Mechanisms shared by crystals of different
chemical nature, size, and shape
Necroinflammation describes the tight link between
inflammation and regulated necrosis, two processes
that can be activated within the same cell, for example,
during the release of extracellular traps from neu-
trophils [52], or in separate cells. For example, cytoki-
nes released from one cell can trigger regulated
necrosis in another, vice versa danger-associated
molecular patterns released from a dying cell trigger
innate immune activation in others [4,53]. Crystals and
nano- and microparticles are potent triggers of
necroinflammation. As mentioned earlier, macrophages
and other phagocytes engulf these crystals or crys-
talline particles. The phagosomes then fuse with the
lysosomes to form phagolysosomes, where lytic pro-
teases attempt to digest the cargo. Crystalline particles
often resist digestion, which can destabilize lysosomes
resulting in lysosomal leakage of lysosomal content
into the cytosol. One of these proteases is cathepsin B
that affects the mitochondrial outer membrane poten-
tial (MOMP) leading to the generation of reactive oxy-
gen species (ROS) [54]. Cathepsin B and ROS activate
the NLRP3 inflammasome to yield mature forms of
IL-1b and IL-18 that set up an inflammatory response
(Fig. 2) [55]. Cytosolic cathepsin B also changes the
conformation of receptor-interacting protein kinase
(RIPK)-1 and turns inhibition into activation of
necroptosis [56,57]. Degradation of RIPK1 induces
oligomerization and phosphorylation of RIPK3, which
Fig. 1. Crystal-related outside-in signaling. Crystals and microparticles induce outside-in signaling in various ways. A series of different
scavenger receptors such as MARCO, SR-A1, SR-B1, and CD36 contributes to intracellular uptake of crystals by phagocytosis. Crystalline
endogenous metabolites, proteins, or microparticles can also interact with other elements of the outer plasma membrane. For example, the
lipid nature of CCs allows direct interaction with cholesterol components inside certain membrane domains. Surface receptors of the C lectin-
type link crystal binding to Syk kinase signaling leading to the activation of either pro- or anti-inflammatory signaling pathways. Certain crystals
also activate complement components on cell surfaces, which can contribute to cell injury. CD, cluster of differentiation; Clec, C-type lectin;
CR, complement receptor; MARCO, macrophage receptor with collagenous structure; MSU, monosodium urate; SR, scavenger receptor.
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in turn phosphorylate, and MLKL [58]. Activated
MLKL undergoes oligomerization and translocation
to nuclear and plasma membranes where it forms
pores, which can induce necroptosis [58,59]. Crystal-in-
duced loss of the MOMP also leads to cyclophilin D
(CYPD)-dependent mitochondrial permeability
transition-related regulated necrosis [60]. A broad
range of environmental and metabolic crystals, for
example, calcium oxalate, MSU, calcium phosphate,
cysteine, cholesterol, asbestos, silica, and titanium
dioxide, have been demonstrated to induce cathepsin B
and ROS-mediated NLRP3 inflammasome activation
Fig. 2. Molecular mechanisms of crystal-induced necroinflammation. The crystal-induced necroinflammation involves the activation of
multiple pathways of necroinflammation. Upon exposure, the cells internalize crystals or crystalline particles into phagosomes. Then,
phagosomes fuse with lysosomes to form phagolysosomes, where several lytic enzymes try to degrade the crystals or crystalline particles.
Failure of degradation induces phagolysosome destabilization leading to the release of several lytic enzymes, for example, cathepsin B in
the cytosol. Cathepsin B cleaves the endogenous inhibitor of necroptosis, RIPK1, and thereby promotes the formation of RIPK3-MLKL
necrosome complex, in the absence of caspase 8. The activated MLKL oligomers then translocate to the plasma membranes where they
induce pore formation leading to necroptosis. These MLKL oligomers also translocate to mitochondria membrane where they induce ROS
formation by opening MPTP in a CypD-dependent manner and lead to mitochondrial permeability transition-related necrosis (MPT-RN). Both
necroptosis and MPT-RN lead to release of DAMPs, alarmins, and histones in the extracellular compartment where they contribute to
inflammation. In addition, RIPK1 also contributes to inflammation via activation of the NFkB via IKK complex. However, in the absence of
caspase 8, RIPK1 activation leads to apoptosis, devoid of inflammation. Cathepsin B also activates the NLRP3 inflammasome that cleaves
pro-IL-1b and pro-IL-18 into mature IL-1b and IL-18, and contribute to inflammation. Moreover, calcium ions released from the
phagolysosomes activate calpains that cleave pro-IL-1a into mature IL-1a and contribute to inflammation. Ca2+, calcium ions; CypD,
cyclophilin D; DAMPs, danger-associated molecular patterns; IL, interleukin; MLKL, mixed lineage kinase domain-like; MPTP, mitochondrial
permeability transition pore; RIPK, receptor-interacting protein kinase; ROS, reactive oxygen species.
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and IL-1b and IL-18 release, as well as RIPK3-
MLKL-mediated necroptosis of epithelial cells and
neutrophils [2,60–64].
Crystal-specific mechanisms
Beyond such shared mechanisms, intracellular uptake
of MSU crystals elicits also a specific effect. The acid-
ity inside phagolysosomes releases sodium ions from
MSU crystals into the cytosol, where they increase
intracellular tonicity and secondary water influx via
osmotic forces. Water influx and cell swelling lower
the intracellular potassium concentration, a known
activator of the NLRP3 inflammasome [65]. Acidity
within lysosomes also mobilizes calcium from calcium
phosphate crystals, a process activating cytosolic cal-
pains [66]. Calpains are calcium-dependent proteases
that contribute to inflammation by cleaving pro-IL-1a
into active IL-1a [66]. In addition, calcium oxalate
crystals induce autophagy, as evident from increased
expression of light chain 3-II and beclin-1 and the
presence of autophagy-related vacuoles [67]. Crys-
talline silica particles inside the phagosome trigger the
assembly of liposomes in the cytoplasm, which leads
to the production of leukotriene B4 in an inflamma-
some-independent manner [68].
Numerous mechanisms minimize
crystal-induced necroinflammation
Beyond the many ways how crystals and microparti-
cles can trigger inflammation, they can also directly
interact on the cell surface to attenuate pro-inflamma-
tory signal pathways. For example, MSU crystals
specifically bind to the myeloid inhibitory Clec-like
receptor Clec-12a on macrophages, dendritic cells, and
neutrophils [15,69].
Microparticle or crystal deposits cause medical
problems also in a noninflammatory or cytotoxic man-
ner, especially in the draining ducts of excretory
organs such as liver and kidney, where calculi can
grow to stones persisting in gall bladder or renal pelvis
that occasionally cause symptomatic obstruction.
Stone growth involves a gradual apposition of mineral
and organic material that may involve some of the
aforementioned molecular mechanisms such as the
sticky nature of chromatin released by NETs [30].
Intrinsic crystallization inhibitors such as citrate of
hypocitrate interfere with further apposition or miner-
als and prevent stone formation in the majority of the
population [70]. As another example, uromodulin, a
sticky glycoprotein selectively secreted by epithelial
cells of the kidney‘s loop of Henle, covers crystals and
calculi in the draining system. Within the urinary tract,
uromodulin is immunologically inert and masks the
pro-inflammatory and cytotoxic potential of crystals,
although once picked up by phagocytes, uromodulin
itself can activate the NLRP3 inflammasome, for
example, when tubular epithelial cell damage exposes
uromodulin particles to resident or infiltrating
mononuclear phagocytes in the kidney [71]. Vascular
deposits of calcium phosphate crystals cause vascular
wall or heart valve calcifications that are a central ele-
ment of numerous cardiovascular complications of dia-
betes and chronic kidney disease [72] and often relate
to a dysbalance of calcification inhibitors such as
matrix Gla protein and fetuin-A [73,74]. These calcium
phosphate deposits are usually devoid of any inflam-
matory response and rather mimic the process of ossi-
fication. Such sclerotic vessels not only lose their
Fig. 3. Mechanisms of crystal granuloma/tophus formation in kidney, lung, and joint. During crystal nephropathy, (A) supersaturation of
calcium oxalate (CaOx) in the urine leads to the formation of CaOx crystals. Crystals adhere on the surface of tubular cells and create a
nidus for crystal growth, which leads to crystal plug formation in the tubular lumen and obstruction of the tubule. (B) Tubular cells
dedifferentiate and grow on the surface of the crystal plug, eventually leading to translocation of the crystal plug into the interstitial
compartment. (C) In the interstitial compartment, frustrated phagocytosis of large crystal plugs triggers the formation of giant cells,
subsequently leading to a granuloma, which isolates the crystal plug from the renal parenchyma. Silicosis is one of the chronic fibrotic
pulmonary diseases caused by inhalation of inorganic occupational dusts like silica particles, which are ingested by alveolar macrophages
(A). Silica crystals cause cytotoxicity to the endothelial cells (B) and the secretion of inflammatory and fibrotic mediators by macrophages
leading to lung remodeling through collagen and elastin deposition (C). Prolonged silica exposure can eventually cause the formation of
interstitial silicotic nodules, which contain macrophages, lymphocytes, and fibroblasts with disorganized collagen patches (D). These silicotic
nodules cause progressive lung fibrosis and reduction of lung volume. Gouty arthritis is associated with MSU crystals inside joints (A), a
process promoted by a local imbalance of uric acid supersaturation. (B) MSU crystals cause an acute inflammatory response characterized
by immune cell infiltration, NET formation, necroptosis, activation, and differentiation of macrophages and dendritic cells. This immune
response will spontaneously resolve after a few days. (C) In contrast to acute gout, chronic tophaceous gout involves persistent MSU
crystal masses (tophi) that cause a smoldering local or systemic inflammation via granuloma-like foreign body reaction. These
granulomatous lesions are comprised of central MSU crystal-NET masses surrounded by mono- and multinucleated phagocytes (giant cells),
lymphocytes, and fibroblast, which leads to cartilage and bone damage.
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compliance but occasionally develop vascular obstruc-
tions followed by tissue necrosis, for example, in calci-
phylaxis [33].
Another unexpected molecular mechanism that sup-
presses crystal-induced inflammation relates to condi-
tions where masses of neutrophils form NETs around
crystals, for example, in gouty arthritis. Indeed, gouty
arthritis is a biphasic MSU crystal-related disease as
the crescendo of pain and swelling is followed by
spontaneous resolution of these signs of inflammation
usually after 3–7 days [75]. The massive influx of neu-
trophils results in the formation of so-called aggre-
gated NETs that are also found in gouty tophi devoid
of intense inflammation in patients with chronic gout.
Aggregated NETs release of large amounts of pro-
teases that digest all locally secreted cytokines and
chemokines, and thereby induce resolution of inflam-
mation and some form of immune anergy [76].
Microparticles entering interstitial compartments of
lungs, skin, or kidney can form crystal granulomas as a
common foreign body reaction (Fig. 3). Indeed, granu-
loma formation is a form of microparticle compartmen-
talization. Silica particles or asbestos fibers cannot be
cleared by phagocytes from the lung and hence trigger
granuloma formation. Such granulomas have a core of
activated phagocytes and an outer aspect of anti-in-
flammatory and profibrotic immune cells, which pro-
mote remodeling and fibrosis of the surrounding
healthy tissue [77]. In the kidney, crystal plugs within
tubules may cause fibrosis also of the surrounding as a
secondary response to nephron loss [78] but interstitial
granuloma formation upon ‘exotubulosis’ of intratubu-
lar crystal plugs into the interstitial compartment has
also been reported [79]. This interesting process starts
from tubular epithelial cells that migrate to the crystal
plug and form a neo-basement membrane between cells
and plug surface (Fig. 3) [79,80]. At the same time,
interstitial macrophages degrade the original basement
membrane below the crystal plug, a coordinated pro-
cess ending in a shift of the crystal plug from the tubule
into the interstitial compartment [80], where it forms a
granuloma [28,79,80].
Thus, crystals can persist in the human body with-
out causing permanent necroinflammation but it
depends on the type of particle, the tissue compart-
ment, and the presence of various immune cells in this
compartment whether crystals form stones, granuloma,
anergic tophi, or bone-like calcifications. However,
crystals remain an irritating factor frequently causing
chronic tissue remodeling, sclerosis, and scaring.
How do crystals trigger thrombosis?
Certain crystals occur in the bloodstream. For exam-
ple, hemozoin crystals are released from erythrocytes
during febrile episodes of malaria and the NLRP3 and
absent in melanoma 2 inflammasomes as well as IL-33
are thought to contribute to systemic inflammation
[81,82]. As another example, spontaneous mechanic
ruptures of atherosclerotic plaques can dislocate CCs
from inside plaques into the bloodstream, where they
flush into peripheral arteria and arterioles. The clinical
presentation of the cholesterol embolism syndrome is
dominated by ischemic tissue injury, and histopatho-
logical examination demonstrates how CCs impact the
vascular wall [83]. However, not the crystals
Fig. 4. CC embolism triggers endovascular clot formation. CC embolism is a complication of advanced atherosclerosis when atheromatous
plaques in larger arterial vessels rupture and release crystalline cholesterol into the bloodstream. Crystals induce injury to endothelial cells of
smaller arteries or arterioles. Injured endothelial cells release nuclear and mitochondrial DNA and tissue factors, which contribute to platelet
activation, plasmatic clotting, release of extracellular traps from NETs, and clot formation. Whenever such crystal clots cause obstruction of
terminal arteries, tissue ischemia and necrosis occur.
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themselves but crystal-related clots obstruct the vascu-
lar lumen and are the cause of tissue ischemia (Fig. 4)
[84]. CCs do not activate platelets directly or induce
clotting of full blood [50] (C. Shi, T. Kim, S. Steiger,
S. R. Mulay, B. M. Klinkhammer, T. B€auerle, M. E.
Melica, P. Romagnani, L. Yang, D. M€ockel, M.
Baues, E. Mammadova-Bach, B. Sanne, J. W. M.
Heemskerk, A. Braun, T. Lammers, P. Boor, H. J.
Anders, unpublished observation) but trigger mechani-
cal injury to endothelial cells and activate comple-
ments, which leads to the release of tissue factor and
nuclear DNA both initiating the clotting process [50]
(C. Shi, T. Kim, S. Steiger, S. R. Mulay, B. M.
Klinkhammer, T. B€auerle, M. E. Melica, P. Romag-
nani, L. Yang, D. M€ockel, M. Baues, E. Mam-
madova-Bach, B. Sanne, J. W. M. Heemskerk, A.
Braun, T. Lammers, P. Boor, H. J. Anders, unpub-
lished observation). The indirect activation of platelets
increases the amount of prothrombotic extracellular
DNA as activated platelets release mitochondrial
DNA (C. Shi, T. Kim, S. Steiger, S. R. Mulay, B. M.
Klinkhammer, T. B€auerle, M. E. Melica, P. Romag-
nani, L. Yang, D. M€ockel, M. Baues, E. Mam-
madova-Bach, B. Sanne, J. W. M. Heemskerk, A.
Braun, T. Lammers, P. Boor, H. J. Anders, unpub-
lished observation) [85]. Also, NETs partially con-
tribute to this process [62] (C. Shi, T. Kim, S. Steiger,
S. R. Mulay, B. M. Klinkhammer, T. B€auerle, M. E.
Melica, P. Romagnani, L. Yang, D. M€ockel, M.
Baues, E. Mammadova-Bach, B. Sanne, J. W. M.
Heemskerk, A. Braun, T. Lammers, P. Boor, H. J.
Anders, unpublished observation). In contrast, small
amounts of CCs that do not cause endothelial cell
injury remain inside the vasculature without triggering
crystal clots [86].
Conclusions
Intrinsic or extrinsic crystals and nano- and micropar-
ticles induce diverse tissue responses. NLRP3-driven
inflammation and several pathways of regulated necro-
sis contribute to acute necroinflammation, for exam-
ple, in acute gouty arthritis or acute dust exposures.
Persistent particle deposits cause foreign body reac-
tions characterized by granuloma formation and tissue
fibrosis. Numerous molecular mechanisms can limit
persistent inflammation in this setting, but these mech-
anisms are diverse and depend on the atomic nature,
shape, and size of the particle deposits. Within the
bloodstream, CC embolism triggers microvascular clot-
ting followed by ischemic tissue infarction and organ
failure. Clearance of microparticles is essential for
body surfaces and excretory organs, and several
mechanisms prevent calculi and stone formation there.
However, a significant proportion of the population
suffers from kidney and gallstones that can cause
obstruction, colic, and other disabling clinical compli-
cations. Studying the shared and specific pathomecha-
nisms should help to develop better therapies for
patients with crystallopathies.
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